Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
R. Sharon Chinthrajah(Stanford University), Kari C. Nadeau(Palo Alto University), Shu‐Chen Lyu(Pulmonary and Allergy Associates), Daniel Petroni(Allergy Asthma Research Institute), Vanitha Sampath(Stanford Health Care), Cherie Liu(Pulmonary and Allergy Associates), Shu Cao(Pulmonary and Allergy Associates), Marco Londei, Andrew Long(Johns Hopkins University), Sayantani Sindher(Johns Hopkins University)
Cited by 188
Related Papers
Prevalence and Severity of Food Allergies Among US Adults
|JAMA Network Open|2019|1k
The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States
|PEDIATRICS|2018|866
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
|Cell|2022|495
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
|Nature Immunology|2022|480
EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1
|Transplantation|1998|404